BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Creabilis Therapeutics Appoints Anthony Wilson as New Chief Executive Officer


6/16/2008 11:18:13 AM

Ivrea, Italy – 16th June, 2008 – Creabilis Therapeutics SpA, an emerging specialty pharmaceutical company focused on dermatology, today announced the appointment of Tony Wilson as Chief Executive Officer with immediate effect. Mr Wilson brings to Creabilis a broad knowledge of the biotechnology and pharmaceutical industry combined with first hand experience of the dermatology sector.

He has over 25 years industry experience gained for the most part at Leo Pharmaceuticals a company engaged in clinical research, manufacture, marketing and sales of Leo Group products in the UK. While at Leo Pharmaceuticals Mr Wilson has been involved in the development and marketing of Dovonex and Dovobet, two of the most successful products in the history of dermatology.

Commenting on his new role, Mr Wilson said:

“Creabilis is at an exciting stage of development and I look forward to contributing to the future growth of the Company. I am convinced that Creabilis is in an excellent position to become a successful dermatology business as it has a rich pipeline of clinical and pre-clinical drug candidates focussed on dermatological indications, a deep understanding of the science behind a number of serious skin disorders, and a driven management team backed by experienced international investors and board members.”

Mr Wilson joins Creabilis from Janus Pharmaceuticals, Inc. a US-headquartered dermatology company with its lead product, luliconazole, a novel topical prescription anti-fungal product, in late stage development in the USA and Europe. Prior to that he was co-founder and CEO of Salveo Pharmaceuticals Ltd. Salveo was a speciality pharmaceutical company whose objectives were to acquire and market dermatology products in Europe.

Claudio Nessi, Partner at NeoMed, said: “We are delighted to have such an experienced industry professional managing Creabilis. Tony brings with him significant understanding of the dermatology market, hands-on experience of developing and commercialising high value brands and has proven abilities in raising funds to allow companies to grow. We are certain Tony will contribute greatly to Creabilis achieving its goal of becoming a specialty pharma company marketing their own new prescription medicines to treat skin diseases in niche indications and through licensing in larger indications.”

For further information please contact:

Creabilis Tony Wilson /Silvio Traversa Tel: +39 0125 53543 E-mail: info@creabilistherapeutics.com

Citigate Dewe Rogerson Chris Gardner or Sylvie Berrebi Tel: +44 (0)20 7282 1050 E-mail: sylvie.berrebi@citigatedr.co.uk

About Creabilis Therapeutics SpA Creabilis Therapeutics is an Italian specialty pharmaceutical company discovering, developing and commercializing new products to treat skin disorders, an area of significant unmet medical need and high commercial potential. Founded in 2003, Creabilis is located in the Bioindustry Park del Canavese Ivrea, Italy. Creabilis’ strategy is to commercialize its products directly through its own marketing efforts in niche indications or through co marketing or licensing with partners in larger indications. The Company has a rich pipeline of clinical and pre-clinical drug candidates focussed on dermatological indications. Its most advanced products are: CT327 for the treatment of psoriasis, dermatitis and other skin conditions characterised by the hyperproliferation of keratinocytes; and CT200 which is being developed for the treatment of Behcet’s Disease. Both products are entering Phase II clinical trials in 2008. In addition, Creabilis has a number of drug candidates in the later pre-clinical stages of development.

For more information, please visit: www.creabilistherapeutics.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES